A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.
暂无分享,去创建一个
M. Barbacid | Marta Puyol | Alberto Martin | P. Dubus | F. Mulero | P. Pizcueta | G. Khan | C. Guerra | D. Santamaría | David Santamaría
[1] M. Serrano,et al. p19ARF links the tumour suppressor p53 to Ras , 1998, Nature.
[2] M. Barbacid,et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia , 1999, Nature Genetics.
[3] P. Pandolfi,et al. Targeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27Kip1 Activity , 1999, Molecular and Cellular Biology.
[4] T. Hupp,et al. Posttranslational Modifications of p53 in Replicative Senescence Overlapping but Distinct from Those Induced by DNA Damage , 2000, Molecular and Cellular Biology.
[5] Ming You,et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice , 2001, Nature Genetics.
[6] J. Harper,et al. A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[7] C. Conti,et al. Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. , 2002, The American journal of pathology.
[8] Marshall W. Anderson,et al. LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer , 2003, Oncogene.
[9] Pierre Dubus,et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice , 2003, Nature Genetics.
[10] Manuel Serrano,et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.
[11] J. Minna,et al. Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non‐small cell lung cancer , 2003, International journal of cancer.
[12] C. Conti,et al. Lack of Cyclin-Dependent Kinase 4 Inhibits c-myc Tumorigenic Activities in Epithelial Tissues , 2004, Molecular and Cellular Biology.
[13] Pierre Dubus,et al. Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6 , 2004, Cell.
[14] R. DePinho,et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.
[15] N. Pryer,et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.
[16] M. Barbacid,et al. Tumour biology: Senescence in premalignant tumours , 2005, Nature.
[17] T. Jacks,et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.
[18] Pierre Dubus,et al. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). , 2005, Cancer cell.
[19] Yan Geng,et al. Requirement for CDK4 kinase function in breast cancer. , 2006, Cancer cell.
[20] Tiansen Li,et al. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. , 2006, Cancer cell.
[21] Dimitris Kletsas,et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.
[22] Aaron Bensimon,et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication , 2006, Nature.
[23] Frédérick A. Mallette,et al. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. , 2007, Genes & development.
[24] Pierre Dubus,et al. Cdk1 is sufficient to drive the mammalian cell cycle , 2007, Nature.
[25] M. Barbacid,et al. Mice thrive without Cdk4 and Cdk2 , 2007, Molecular oncology.
[26] C. Bassing,et al. Genotoxic Stress-Induced Cyclin D1 Phosphorylation and Proteolysis Are Required for Genomic Stability , 2008, Molecular and Cellular Biology.
[27] D. Peeper,et al. Cellular senescence in vivo: a barrier to tumorigenesis. , 2008, Current opinion in cell biology.
[28] Allan Balmain,et al. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer , 2008, Nature Genetics.
[29] James R Bischoff,et al. CDK inhibitors in cancer therapy: what is next? , 2008, Trends in pharmacological sciences.
[30] Ben S. Wittner,et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.
[31] Jun Yokota,et al. A gene‐alteration profile of human lung cancer cell lines , 2009, Human mutation.
[32] Sridhar Ramaswamy,et al. Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.
[33] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[34] A. Giordano,et al. Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.
[35] M. Barbacid,et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene , 2010, Nature Cell Biology.